AR111908A1 - Composiciones terapéuticas y métodos de tratamiento de hepatitis b - Google Patents

Composiciones terapéuticas y métodos de tratamiento de hepatitis b

Info

Publication number
AR111908A1
AR111908A1 ARP180101455A ARP180101455A AR111908A1 AR 111908 A1 AR111908 A1 AR 111908A1 AR P180101455 A ARP180101455 A AR P180101455A AR P180101455 A ARP180101455 A AR P180101455A AR 111908 A1 AR111908 A1 AR 111908A1
Authority
AR
Argentina
Prior art keywords
hepatitis
treatment
methods
therapeutic compositions
human
Prior art date
Application number
ARP180101455A
Other languages
English (en)
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of AR111908A1 publication Critical patent/AR111908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicación 1: Un método para tratar la hepatitis B en un ser humano, que comprende administrarle al ser humano: un ARNip que se dirige a una parte del genoma de VHB; un inhibidor de PD-L1; y una vacuna anti-VHB.
ARP180101455A 2017-05-31 2018-05-31 Composiciones terapéuticas y métodos de tratamiento de hepatitis b AR111908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513261P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
AR111908A1 true AR111908A1 (es) 2019-08-28

Family

ID=64455651

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101455A AR111908A1 (es) 2017-05-31 2018-05-31 Composiciones terapéuticas y métodos de tratamiento de hepatitis b

Country Status (6)

Country Link
US (1) US20220265817A1 (es)
EP (1) EP3634431A4 (es)
AR (1) AR111908A1 (es)
CA (1) CA3065518A1 (es)
TW (2) TW202539707A (es)
WO (1) WO2018222910A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2840101A1 (de) 2013-08-23 2015-02-25 BASF Coatings GmbH Dimerfettsäure-haltiges Reaktionsprodukt und ein das Reaktionsprodukt enhaltendes Beschichtungsmittel
JP7616987B2 (ja) 2018-07-13 2025-01-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
CA3130596A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
AU2020312734B2 (en) 2019-07-18 2025-11-20 Enyo Pharma Improved treatment using EYP001
EP3999069B1 (en) * 2019-07-18 2023-10-11 ENYO Pharma Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection
EP4031140A1 (en) * 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Method of treating hbv infection using a core protein allosteric modulator
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
CN114828852A (zh) * 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
CN117320722A (zh) * 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
WO2025260241A1 (zh) * 2024-06-18 2025-12-26 复旦大学 一种用于增强乙肝患者免疫应答的抗原抗体复合物疫苗及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890403A4 (en) * 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
EP3139954A4 (en) * 2014-05-09 2018-02-28 Indiana University Research and Technology Corporation Methods and compositions for treating hepatitis b virus infections
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
SG11201703638XA (en) * 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
SG11201909572QA (en) * 2017-04-18 2019-11-28 Alnylam Pharmaceuticals Inc Methods for the treatment of subjects having a hepatitis b virus (hbv) infection

Also Published As

Publication number Publication date
US20220265817A1 (en) 2022-08-25
EP3634431A1 (en) 2020-04-15
WO2018222910A1 (en) 2018-12-06
TW202539707A (zh) 2025-10-16
CA3065518A1 (en) 2018-12-06
EP3634431A4 (en) 2021-06-23
TW201907009A (zh) 2019-02-16

Similar Documents

Publication Publication Date Title
MX2022011756A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
CR20160520A (es) Oligómeros y conjugados de oligómeros
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
NZ780244A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
MX2021006954A (es) Terapia combinada contra el virus de la hepatitis b (vhb).
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
TW201613617A (en) Methods for the treatment of hepatitis B and hepatitis D virus infections
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
MX2021013594A (es) Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d

Legal Events

Date Code Title Description
FB Suspension of granting procedure